• The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).

      Valenciano, Marta; Kissling, Esther; Reuss, Annicka; Jiménez-Jorge, Silvia; Horváth, Judit K; Donnell, Joan M O; Pitigoi, Daniela; Machado, Ausenda; Pozo, Francisco; 1Epidemiology Department, EpiConcept, Paris, France. Electronic address: m.valenciano@epiconcept.fr. 2Epidemiology Department, EpiConcept, Paris, France. 3Department for Infectious Disease Epidemiology Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany. 4National Centre of Epidemiology/CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. 5Department of Public Health, Strategic Planning and Epidemiology, Office of the Chief Medical Officer, Budapest, Hungary. 6Health Protection Surveillance Centre, Dublin, Ireland. 7UMF Carol Davila, INCDMI Cantacuzino, Bucharest, Romania. 8Department of Epidemiology, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal. 9National Centre for Microbiology, National Influenza Centre-Institute of Health Carlos III, Madrid, Spain. (2015-06-04)
      In the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. In 2013-2014, we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in six European Union (EU) countries to measure 2013-2014 influenza VE against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Influenza A(H3N2) and A(H1N1)pdm09 viruses co-circulated during the season.